Sugi Predict

Sugi Predict / Targets / CCND1

CCND1

G1/S-specific cyclin-D1 · P24385 · CCND1 on Sugi Atlas →

165,796 patent compounds predicted against CCND1, 97,804 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL189662 SCHEMBL189662 1.00 20/20
SCHEMBL188565 SCHEMBL188565 0.53 19/20
SCHEMBL189897 SCHEMBL189897 0.53 19/20
SCHEMBL190547 SCHEMBL190547 0.61 18/20
SCHEMBL189845 SCHEMBL189845 0.55 18/20
SCHEMBL190132 SCHEMBL190132 0.62 15/20
SCHEMBL188528 SCHEMBL188528 0.60 12/20
Alvocidib Alvocidib (SCHEMBL3651) 1.00 11/20
Alvocidib Alvocidib (SCHEMBL3652) 1.00 11/20
SCHEMBL189169 SCHEMBL189169 0.55 11/20
SCHEMBL31622 SCHEMBL31622 0.51 10/20
SCHEMBL188747 SCHEMBL188747 0.52 9/20
SCHEMBL205896 SCHEMBL205896 0.50 9/20
SCHEMBL111391 SCHEMBL111391 0.73 8/20
SCHEMBL12466 SCHEMBL12466 0.57 8/20
SCHEMBL137707 SCHEMBL137707 0.57 8/20
SCHEMBL190014 SCHEMBL190014 0.46 8/20
SCHEMBL205605 SCHEMBL205605 0.45 8/20
SCHEMBL112928 SCHEMBL112928 0.72 7/20
SCHEMBL12292 SCHEMBL12292 0.59 7/20

Clinical trials — most relevant to CCND1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt PHASE4COMPLETED
Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma PHASE1/PHASE2RECRUITING
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas PHASE2RECRUITING
LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE) PHASE2COMPLETED
Cyclin D1 Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at Clinical N2 Stage PHASE2RECRUITING
Cetuximab Plus Dalpicilib in Patients With HPV Negative, PD-1 Resistant R/M HNSCC PHASE2COMPLETED
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6 PHASE2RECRUITING
Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma PHASE2COMPLETED
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer PHASE2UNKNOWN
Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B) PHASE2ACTIVE_NOT_RECRUITING
Efficacy of Palbociclib in Advanced Acral Melanoma With Cell Cycle Gene Aberrations PHASE2UNKNOWN
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) PHASE1/PHASE2RECRUITING
Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma PHASE2ACTIVE_NOT_RECRUITING
Bortezomib in Treating Patients With Advanced or Metastatic Sarcoma PHASE2COMPLETED
Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression PHASE2COMPLETED
Evaluation of ABEMACICLIB Monotherapy in Patients With Locally Advanced/Metastatic Head and Neck Cancer After Failure of Platinum and Cetuximab or Anti-EGFR-based Therapy and Harboring an Homozygous Deletion of CDKN2A, and/or an Amplification of CCND1 and/or of CDK6 PHASE2COMPLETED
Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02) PHASE2UNKNOWN
Efficacy and Safety of Neridronate (Nerixia®)to Treat Osteoporosis in Patients With TM and TI PHASE2COMPLETED
Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms PHASE1COMPLETED
Study of FCN-437c in Patients With Advanced Solid Tumors PHASE1COMPLETED
Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations PHASE1ACTIVE_NOT_RECRUITING
AZD1775 for Advanced Solid Tumors PHASE1COMPLETED
Erlotinib in Treating Patients With Barrett Esophagus PHASE1UNKNOWN
Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors PHASE1COMPLETED
Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients PHASE1COMPLETED
Alisertib and Combination Chemotherapy in Treating Patients With Gastrointestinal Tumors PHASE1COMPLETED
the Efficacy and Safety of Dalpiciclib Combined With Third-generation EGFR-TKI in Patients With EGFR Mutation and Meningial Metastasis in Non-small Cell Lung Cancer Progressing Through Third-generation TKI and Platinum-containing Two-drug Chemotherapy nanUNKNOWN
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer nanCOMPLETED
Prospective Validation of a DNA Damage Repair-Hippo Pathway Signature in Patients With Advanced Gastric Cancer nanUNKNOWN
Cell Cycle Regulatory Gene Study in Patients With Myeloproliferative Disorders nanWITHDRAWN

Related proteins — ESM-2 sequence neighbours (a CCND1 binder may also engage these)

ProteinNameSimilarity
P25322 — 1.000 P25322 →
P39948 — 1.000 P39948 →
Q5R6J5 — 1.000 Q5R6J5 →
Q64HP0 — 1.000 Q64HP0 →
Q2KI22 — 1.000 Q2KI22 →
P55169 — 1.000 P55169 →
Q90459 — 0.999 Q90459 →
P50755 — 0.995 P50755 →
Q8WNW2 — 0.995 Q8WNW2 →
Q0P5D3 — 0.994 Q0P5D3 →
P30280 — 0.994 P30280 →
CCND2 G1/S-specific cyclin-D2 0.993 landscape →
Q04827 — 0.993 Q04827 →
P49706 — 0.993 P49706 →
P53782 — 0.990 P53782 →
CCNE1 G1/S-specific cyclin-E1 0.987 landscape →
Q9D995 — 0.986 Q9D995 →
P50756 — 0.985 P50756 →
Q91780 — 0.985 Q91780 →
Q8N815 — 0.985 Q8N815 →
P47794 — 0.984 P47794 →
Q61457 — 0.984 Q61457 →
O42575 — 0.982 O42575 →
P49707 — 0.982 P49707 →
P39949 — 0.981 P39949 →
P30282 — 0.981 P30282 →
CCNE2 G1/S-specific cyclin-E2 0.981 landscape →
P48961 — 0.981 P48961 →
O15995 — 0.980 O15995 →
CCND3 G1/S-specific cyclin-D3 0.980 landscape →